Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 25 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

HCV infection in HIV patients does not increase risk of death or developing AIDS

Infection with hepatitis C virus (HCV) does not appear to increase the risk of death or developing AIDS for HIV patients, nor decrease the response to effective antiretroviral treatment, according to an article to be published in the next issue of the Journal of the American Medical Association.

News image

fiogf49gjkf04

Mark S. Sulkowski, of Johns Hopkins University School of Medicine, Baltimore, Maryland, USA, and colleagues conducted a study to assess the effect of HCV infection on clinical and immunologic progression of HIV infection and immunologic response to highly active antiretroviral therapy (HAART).

Co-author Richard E. Chaisson, presented the findings of the research at a JAMA media briefing at the International AIDS Conference in Barcelona, Spain.

According to background information in the article, there are conflicting reports regarding the effect of HCV on the progression of HIV disease.

HIV infection appears to increase the likelihood that HCV infection will become chronic, and, in most studies, increase the risk of progressive HCV-related liver disease.

Due to shared routes of transmission such as by contaminated needles, an estimated 15-30% of HIV-infected persons are coinfected with HCV in the United States and Europe.

The study included 1955 patients enrolled between 1995 and 2001 at the Johns Hopkins Hospital HIV Clinic.

The patients had at least one return visit to the clinic and were free of AIDS at enrolment.

45% of the patients had HCV and HIV coinfection.
Journal of the American Medical Association

It was found that 45% of patients had HCV infection. Median length of follow-up was 2.2 years for HCV-infected and 2.0 years for HCV-uninfected patients.

The authors found, "After adjustment for the administration of HAART and its effectiveness, we did not detect an increased risk of development of AIDS-defining illness, death, or CD4 cell count decline to below 200/µl among HCV-infected compared with HCV-uninfected patients.

"In addition, among patients prescribed HAART, we found no evidence that HCV infection alters the virological or immunologic response to potent antiretroviral therapy."

Comparing HCV-infected patients with HCV-uninfected patients, there were no significant differences for acquiring an AIDS-defining illness (26% vs 24%, respectively) or risk of death (18% vs 16%).

Among patients treated with HAART, HCV status was not associated with HIV suppression or CD4 cell response. However, fewer HCV-infected patients received HAART (54%) compared with HCV-uninfected patients (67%).

"Further research is still needed to understand the effect of HCV infection on HIV disease and immune reconstitution in response to HAART.

"However, these findings emphasize the importance of the consideration of effective antiretroviral therapy for HCV-infected and HCV-uninfected persons at immediate risk for the development of AIDS," the authors conclude.

In an accompanying editorial, Stephen J. Rossi and colleagues of the Department of Veterans Affairs Medical Center, and the University of California, San Francisco, comment on the study.

"How should these studies guide clinicians in the management of patients with HCV/HIV coinfection?

"It is likely that many patients with HIV and HCV coinfection will be unable to be treated effectively with current HCV regimens," the authors continue.

"The HCV therapy should be initiated in patients who are expected to tolerate treatment, either before HIV therapy if the latter can be delayed, or during HIV therapy, to delay progression of liver disease.

"Optimal HCV/HIV management will require educating clinicians about the potential for drug interactions between HCV and HIV therapies, continued education of patients about the importance of adherence to prescribed regimens, and for both, education about the importance of alcohol cessation," the authors write.

"Certainly, the patient with coinfection highlights the importance of developing improved HCV regimens that avoid the toxicities of current interferon-based therapies."

JAMA 2002; 288:199-206, 241-3
08 July 2002

Go to top of page Email this page Email this page to a colleague

 23 February 2018 
Patients on antithrombotic agents undergoing emergency and elective endoscopy
 23 February 2018 
Heavy metals on a gluten-free diet
 23 February 2018 
MRI and NAFLD
 22 February 2018 
Outcomes with Crohn’s after infliximab withdrawal
 22 February 2018 
Elderly onset of IBD

 22 February 2018 
Autophagy enhancers
 21 February 2018 
Management of hemorrhoids in the USA
 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 20 February 2018 
Complications and surveillance colonoscopies
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us